Cargando…

Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study

Trabectedin is a therapeutic option for patients with advanced sarcoma. While a randomized trial demonstrated its prolonged progression-free survival (PFS), the reported PFS was <6 months. Some patients can achieve long-term disease control with this treatment. However, the reference information...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohmoto, Akihiro, Nakano, Kenji, Fukuda, Naoki, Wang, Xiaofei, Urasaki, Tetsuya, Hayashi, Naomi, Suto, Hirotaka, Udagawa, Shohei, Oki, Ryosuke, Sato, Yasuyoshi, Yunokawa, Mayu, Ono, Makiko, Saito, Masanori, Minami, Yusuke, Hayakawa, Keiko, Tanizawa, Taisuke, Ae, Keisuke, Matsumoto, Seiichi, Tomomatsu, Junichi, Takahashi, Shunji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977011/
https://www.ncbi.nlm.nih.gov/pubmed/36857355
http://dx.doi.org/10.1371/journal.pone.0280508
_version_ 1784899201298071552
author Ohmoto, Akihiro
Nakano, Kenji
Fukuda, Naoki
Wang, Xiaofei
Urasaki, Tetsuya
Hayashi, Naomi
Suto, Hirotaka
Udagawa, Shohei
Oki, Ryosuke
Sato, Yasuyoshi
Yunokawa, Mayu
Ono, Makiko
Saito, Masanori
Minami, Yusuke
Hayakawa, Keiko
Tanizawa, Taisuke
Ae, Keisuke
Matsumoto, Seiichi
Tomomatsu, Junichi
Takahashi, Shunji
author_facet Ohmoto, Akihiro
Nakano, Kenji
Fukuda, Naoki
Wang, Xiaofei
Urasaki, Tetsuya
Hayashi, Naomi
Suto, Hirotaka
Udagawa, Shohei
Oki, Ryosuke
Sato, Yasuyoshi
Yunokawa, Mayu
Ono, Makiko
Saito, Masanori
Minami, Yusuke
Hayakawa, Keiko
Tanizawa, Taisuke
Ae, Keisuke
Matsumoto, Seiichi
Tomomatsu, Junichi
Takahashi, Shunji
author_sort Ohmoto, Akihiro
collection PubMed
description Trabectedin is a therapeutic option for patients with advanced sarcoma. While a randomized trial demonstrated its prolonged progression-free survival (PFS), the reported PFS was <6 months. Some patients can achieve long-term disease control with this treatment. However, the reference information is insufficient. Herein, we retrospectively reviewed 51 sarcoma patients who received trabectedin. We analyzed the clinicopathological features, trabectedin dose, administration schedule, and clinical outcomes, including the overall response rate (ORR) and PFS. Among them, we assessed the detailed data of patients who achieved long-term disease control (PFS >1 year). The ORR in the 49 evaluable patients was 8%, and the median PFS in 51 patients was 7.5 months. Six patients (12%) achieved PFS of >1 year. Five of the six patients had metastatic lesions at trabectedin initiation. The pathological subtypes were myxoid liposarcoma (n = 2), leiomyosarcoma (n = 2), synovial sarcoma (n = 1), and Ewing sarcoma (n = 1). The final administration dose was the minimum dose (0.8 mg/m(2)) in two patients who continued the treatment over 20 cycles. The best radiological response was partial response (PR) in two myxoid liposarcoma patients and stable disease in four. The durations from trabectedin initiation to the first response in the two PR cases were 163 and 176 days, respectively. Our results support the validity of continuing trabectedin at a sustainable dose and interval in patients who can tolerate it. These results may be useful when considering the clinical application of trabectedin.
format Online
Article
Text
id pubmed-9977011
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-99770112023-03-02 Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study Ohmoto, Akihiro Nakano, Kenji Fukuda, Naoki Wang, Xiaofei Urasaki, Tetsuya Hayashi, Naomi Suto, Hirotaka Udagawa, Shohei Oki, Ryosuke Sato, Yasuyoshi Yunokawa, Mayu Ono, Makiko Saito, Masanori Minami, Yusuke Hayakawa, Keiko Tanizawa, Taisuke Ae, Keisuke Matsumoto, Seiichi Tomomatsu, Junichi Takahashi, Shunji PLoS One Research Article Trabectedin is a therapeutic option for patients with advanced sarcoma. While a randomized trial demonstrated its prolonged progression-free survival (PFS), the reported PFS was <6 months. Some patients can achieve long-term disease control with this treatment. However, the reference information is insufficient. Herein, we retrospectively reviewed 51 sarcoma patients who received trabectedin. We analyzed the clinicopathological features, trabectedin dose, administration schedule, and clinical outcomes, including the overall response rate (ORR) and PFS. Among them, we assessed the detailed data of patients who achieved long-term disease control (PFS >1 year). The ORR in the 49 evaluable patients was 8%, and the median PFS in 51 patients was 7.5 months. Six patients (12%) achieved PFS of >1 year. Five of the six patients had metastatic lesions at trabectedin initiation. The pathological subtypes were myxoid liposarcoma (n = 2), leiomyosarcoma (n = 2), synovial sarcoma (n = 1), and Ewing sarcoma (n = 1). The final administration dose was the minimum dose (0.8 mg/m(2)) in two patients who continued the treatment over 20 cycles. The best radiological response was partial response (PR) in two myxoid liposarcoma patients and stable disease in four. The durations from trabectedin initiation to the first response in the two PR cases were 163 and 176 days, respectively. Our results support the validity of continuing trabectedin at a sustainable dose and interval in patients who can tolerate it. These results may be useful when considering the clinical application of trabectedin. Public Library of Science 2023-03-01 /pmc/articles/PMC9977011/ /pubmed/36857355 http://dx.doi.org/10.1371/journal.pone.0280508 Text en © 2023 Ohmoto et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ohmoto, Akihiro
Nakano, Kenji
Fukuda, Naoki
Wang, Xiaofei
Urasaki, Tetsuya
Hayashi, Naomi
Suto, Hirotaka
Udagawa, Shohei
Oki, Ryosuke
Sato, Yasuyoshi
Yunokawa, Mayu
Ono, Makiko
Saito, Masanori
Minami, Yusuke
Hayakawa, Keiko
Tanizawa, Taisuke
Ae, Keisuke
Matsumoto, Seiichi
Tomomatsu, Junichi
Takahashi, Shunji
Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study
title Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study
title_full Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study
title_fullStr Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study
title_full_unstemmed Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study
title_short Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study
title_sort clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: a retrospective study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977011/
https://www.ncbi.nlm.nih.gov/pubmed/36857355
http://dx.doi.org/10.1371/journal.pone.0280508
work_keys_str_mv AT ohmotoakihiro clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT nakanokenji clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT fukudanaoki clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT wangxiaofei clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT urasakitetsuya clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT hayashinaomi clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT sutohirotaka clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT udagawashohei clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT okiryosuke clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT satoyasuyoshi clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT yunokawamayu clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT onomakiko clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT saitomasanori clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT minamiyusuke clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT hayakawakeiko clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT tanizawataisuke clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT aekeisuke clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT matsumotoseiichi clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT tomomatsujunichi clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy
AT takahashishunji clinicalcharacteristicsofsarcomacasesinwhichlongtermdiseasecontrolwasachievedwithtrabectedintreatmentaretrospectivestudy